STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

| | |
|---|---|
| USAN (OP-138) | SUROVATAMIG |
| PRONUNCIATION | soo rov" a ta' mig |
| THERAPEUTIC CLAIM | Treatment of hematologic malignancies and autoimmune diseases |

CHEMICAL NAME

Immunoglobulin G4 [231-proline,237-alanine,238-alanine,369-tryptophan],bispecific, anti-(human CD3 antigen) (human monoclonal AZD0486 γ4-chain) disulfide with human monoclonal AZD0486 k-chain, (229→124'),(232→127')-bis(disulfide) with immunoglobulin [126-proline,132-alanine,133-alanine] anti-(CD19 antigen) (human single-domain variable region) fusion protein with 219-447-immunoglobulin G4[228-proline,234-alanine,235-alanine,366-serine,368-alanine,407-valine] (human monoclonal AZD0486 γ4-chain)

STRUCTURAL FORMULA

*HC1 (CD3 heavy chain amino acid sequence)*

```
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSG 50
ISWNSGSIGY ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TALYYCAKDS 100
RGYGDYRLGG AYWGQGTLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TKTYTCNVDH KPSNTKVDKR VESKYGPPCP PCPAPEAAGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ 350
VYTLPPSQEE MTKNQVSLWC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 450
```

*LC (CD3 kappa light chain amino acid sequence)*

```
EIVMTQSPAT LSVSPGERAT LSCRASQSVS SNLAWYQQKP GQAPRLLIYG 50
ASTRATGIPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPWTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

*HC2 (CD19 heavy chain amino acid sequence)*

```
EVQLVESGGG LVQPGGSLRL SCAASGFSFS DFWMSWVRQA PGKGLEWVAT 50
ISQAGSEKDY VDSVKGRFTI SRDNAKKSLY LQMNSLRAED TAVYYCASGV 100
YSFDYRGQGT LVTVSSESKY GPPCPPCPAP EAAGGPSVFL FPPKPKDTLM 150
ISRTPEVTCV VVDVSQEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTYRV 200
VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ PREPQVYTLP 250
PSQEEMTKNQ VSLSCAVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 300
SFFLVSRLTV DKSRWQEGNV FSCSVMHEAL HNHYTQKSLS LSLGK 345
```

Note: the main molecular form of the antibody does not contain the heavy chain C-terminal lysines (Heavy Chain 1: Lys-450, Heavy Chain 2: Lys-345) due to C-terminal lysine clipping.

*Disulfide bridges*

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 150-206 | 264-324 | 370-428 |
| | 22"-96" | no CH1 | 159"-219" | 265"-323" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| Inter-H-L (CH1 10-CL 126) | 137-214' | | | |
| Inter-H-H (h 8, h 11) | 229-124" | 232-127" | | |

N-glycosylation sites
H CH2 N84.4:
300, 195"
Fucosylated complex bi-antennary CHO-type glycans

C-terminal lysine clipping
H CHS K2:
450, 345"

| | |
|---|---|
| MOLECULAR FORMULA | $C_{4898}H_{7532}N_{1314}O_{1532}S_{35}$ |
| MOLECULAR WEIGHT | 110.46 kDa |
| TRADEMARK | None as yet |
| SPONSOR | AstraZeneca |
| CODE DESIGNATIONS | AZD0486 (formerly TNB-486) |
| CAS REGISTRY NUMBER | 2892667-02-4 |
| UNII | 3QW12I37H1 |
| WHO NUMBER | 13199 |

GBK